Nonenzymatic cytosolic fatty acid binding proteins (FABPs) are abundantly expressed in many animal tissues with high rates of fatty acid metabolism. No physiological role has been demonstrated for any FABP, although these proteins have been implicated in transport of free long-chain fatty acids (LCFAs) and protection against LCFA toxicity. We report here that mice lacking heart-type FABP (H-FABP) exhibit a severe defect of peripheral (nonhepatic, non-fat) LCFA utilization. In these mice, the heart is unable to efficiently take up plasma LCFAs, which are normally its main fuel, and switches to glucose usage. Altered plasma levels of LCFAs, glucose, lactate and ␤-hydroxybutyrate are consistent with depressed peripheral LCFA utilization, intensified carbohydrate usage, and increased hepatic LCFA oxidation; these changes are most pronounced under conditions favoring LCFA oxidation. H-FABP deficiency is only incompletely compensated, however, causing acute exercise intolerance and, at old age, a localized cardiac hypertrophy. These data establish a requirement for H-FABP in cardiac intracellular lipid transport and fuel selection and a major role in metabolic homeostasis. This new animal model should be particularly useful for investigating the significance of peripheral LCFA utilization for heart function, insulin sensitivity, and blood pressure.-Binas, B., Danneberg, H., McWhir, J., Mullins, L., Clark, A. J. Requirement for the hearttype fatty acid binding protein in cardiac fatty acid utilization. FASEB J. 13, 805-812 (1999) 
are metabolized at high rates by numerous tissues including cardiomyocytes, red skeletal muscle, kidney, hepatocytes, small intestinum, and adipocytes. Before being utilized intracellularly, they have to cross numerous barriers, including the aqueous cytosol. As the solubility of LCFAs in the cytosol is poor, their massive cytosolic flux requires a facilitative mechanism (1) . Fatty acid binding proteins (FABPs), a widely expressed and genetically related family of small cytosolic proteins that specifically and reversibly bind LCFAs, may function as the principal vehicles of cytosolic LCFA transport (2, 3; reviewed in ref 4) . It has, however, turned out to be surprisingly difficult to obtain firm evidence for this notion (5), probably because FABP-mediated LCFA fluxes require an LCFA concentration gradient that is not easily maintained or reconstituted in vitro. Support for the ability of FABPs to facilitate LCFA transport in living cells has come only recently from transfection studies with intestinal and liver FABP (6, 7) , but a contribution of these or other FABPs to LCFA transport in vivo, where higher LCFA fluxes occur, remains uncertain. All current in vivo data on FABPs are correlative and also compatible with other functions, such as cell signaling or protection against LCFA cytotoxicity (reviewed in ref 5) . The existence of at least one unrelated protein potentially capable of transporting LCFAs within the cell (8) further cautions that it is not sufficient to demonstrate a functional ability of an FABP in vitro to draw conclusions about its biological importance.
Deletion of endogenous gene expression within its normal in vivo context is potentially the most convincing way to demonstrate a functional significance, although this approach carries the risk of unwanted compensation (9) . As FABPs show interesting expression patterns that reflect the division of labor between various organ systems, such a strategy may also create useful animal models for investigating regional aspects of LCFA metabolism. Heart-type FABP (H-FABP) is extremely abundant in mature cardiomyocytes, cells normally fueled mainly by mitochondrial oxidation of LCFAs; it is also abundant in red skeletal muscle, moderately expressed in numerous other peripheral organs, and completely absent in liver, white fat, and intestine (10 -13) . In cardiac and red skeletal muscle, H-FABP appears to be the only representative of its family. The expression pattern and assumed significance for LCFA transport suggest this protein is important for peripheral LCFA metabolism.
To both clarify the role of a prototypical FABP in LCFA transport and create a genetic model with which to investigate the physiological and pathophysiological significance of cardiac and other peripheral LCFA fluxes, we deleted the H-FABP gene in laboratory mice by gene targeting technology. The resulting phenotype confirms the viability of this approach by demonstrating for the first time a requirement for an FABP in cellular LCFA utilization. H-FABP-deficient mice show a dramatic switch in cardiac fuel selection and provide a new genetic model of metabolic cardiac hypertrophy. Combined with the analysis of blood plasma metabolites and of the physical performance of H-FABP-deficient mice, the data reveal a major role of H-FABP for fuel metabolism in the whole body.
MATERIALS AND METHODS

Creation of H-FABP-deficient mice
A clone containing the ca. 8 kb H-FABP gene (GenBank accession number U02884) and its flanking regions was isolated from a genomic mouse (strain 129/Ola) P1 library. The short homology arm of the targeting vector was isolated from the 3Ј flank of the H-FABP gene as a 2 kb BamHI-XbaI fragment and cloned (Xba site end-filled) into the BamHI/ SmaI-opened polylinker of pBT/PGK-HPRT (RI). pBT/PGK-HPRT (RI) is pBluescript II SK(ϩ) (Stratagene, La Jolla, Calif.) carrying a 2. 7 kb EcoRI fragment (a hypoxanthine phosphoribosyl transferase (HPRT) minigene under the control of the mouse phosphoglycerate kinase gene promoter), which stems from plasmid PGK/pDWM1 (14) . The long (6 kb) homology arm was isolated as an EcoRI-ScaI fragment from the 5Ј flank of the H-FABP gene, end-filled, cloned into the end-filled HindIII site of pBluescript, then excised with EcoRV and SalI and transferred into the short arm/HPRT construct. Finally, a NotI fragment containing the 2 kb SP-thymidine kinase minigene (TK) was inserted to complete the replacement type targeting vector depicted in Fig. 1A . After linearization with SalI, electroporation into embryonic stem (HM1) (15) cells, and selection with HAT/ganciclovir, homologous recombination was identified by polymerase chain reaction amplification of a 2.5 kb diagnostic fragment (see Fig. 1A ) using primers 5Ј-taaagcgcatgctccagactgcc and 5Ј-cattgttccatcgccagcacatc at an annealing/extension temperature of 68°C in the presence of 5% glycerol/2% DMSO. Two independent ES cell clones were used for blastocyst injection and yielded germ line chimeras after embryo transfer. Experiments were performed with mice of a 129xBalb/c background; comparisons were made between mice of the same age (3 months if not otherwise indicated) and sex, mostly male. The institutional authorities approved all animal experiments.
Southern, Northern, and Western blotting
DNA and total RNA were isolated by proteinase K digestion/ isopropanol precipitation and the TRIZOL (Life Technologies, Paisley, U.K.) procedure, respectively. Southern and Northern blotting were performed according to standard methods (16) using random-primed 32 P-labeled DNA probes: for Southern blots, a 2.2 kb-BamHI-EcoRI genomic fragment just downstream of the short homology arm (Fig. 1A) ; and for Northern blots, cDNAs coding for H-FABP (17) and other FABPs (4), mouse FAT (18), rat muscle CPT1 (19) , rat LCAD (long-chain acyl CoA dehydrogenase) (20) , and rat atrial natriuretic peptide (ANP) (21) . Positive controls for FABP mRNA expression were white fat (ALBP), olfactory bulb (B-FABP), skin (E-FABP), and liver (L-FABP). Northern blots were quantified with a FUJIX BAS2000 phosphorimager. For Western blotting, snap-frozen tissues were powdered, boiled in 10% sodium dodecyl sulfate, and microfuged; supernatants were used for protein determination (BCA; Pierce, Rockford, Ill.) and 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. After transfer to nitrocellulose and blocking with 1% bovine serum albumin/0.01% Tween 20, filters were incubated with a 1:100 -1:500 dilution of a rabbit anti-mouse H-FABP antiserum, washed, and developed using Amersham's ECL chemiluminescence kit.
Diets
Diets were purchased from SNIFF (Soest, Germany). The standard diet contained ca. 45% digestible carbohydrates, 22% protein (supplemented with methionine and lysine), 4.5% fat, the remainder vitamins, minerals, and nondigestible. In one set of experiments, a ketogenic diet containing 35% fat (here, a 60/40 mix of porcine lard and hardened sunflower oil), 15% casein, 40% of a mix of cellulose and Aerosil, and 10% of standard addition of minerals, vitamins, and methionine was used. C decreased to 39 Ϯ 12% (wild-type) and 33 Ϯ 8% (nullizygotes). Mice were killed by cervical dislocation and the organs were excised (blood was released from heart chambers), rinsed in isotonic saline, blotted onto filter paper to remove excessive fluid, weighed, and the radioactivity was counted directly ( 125 I) or after liquefaction with a tissue solubilizer ( 14 C). Uptakes are given as (R1/W)/R2; R1 is the radioactivity of the organ piece, W its wet weight (grams), and R2 the radioactivity of 10 l of blood taken 5 min after injection; division by R2 corrects for small differences in injected radioactivities or plasma volumes.
Tracer studies
Metabolite measurements
Blood was withdrawn from the retro-orbital vein, mixed with EDTA, and an aliquot was used for glucose determination in a clinical laboratory after brief storage at 4°C. The bulk was centrifuged at low speed and the supernatant was either frozen for later determination of lactate, cholesterol, triglycerides and ␤-hydroxybutyrate in a clinical laboratory or used after less than 24 h at 4°C to determine nonesterified fatty acids with the half micro kit from Boehringer Mannheim (Mannheim, Germany).
Distribution of muscle fiber sizes
Paraffin sections of mouse hearts were stained by the periodic acid Schiff-reaction; fibers parallel to the level of sectioning, with diameters falling into the indicated 2.5 M intervals, were counted. Data are pooled for three mice (12 months old) per genotype; the same number of sections was analyzed per mouse and a comparable number of fibers was counted on each section.
Swim training
Mice of both genotypes were collectively placed into a 56 ϫ 37 cm water thermostat fixed at 35°C. Training was for 10 (experiment 1) or 30 (experiment 2) min initially, with daily increases of 10 min from day 2 (experiment 1) or day 4 (experiment 2) onward, up to a final training period of 90 min, which was maintained until the end.
RESULTS
After deletion of one allele of the H-FABP gene (ϳ8 kb) in embryonic stem cells (Fig. 1A) , hemizygous (H-FABP ϩ/Ϫ ) and nullizygous (H-FABP -/-) mice were derived (Fig. 1B) . Nullizygous mice are viable and show no macroscopic abnormalities; they exhibit a normal sex ratio, weight gain, and fertility, and raise their offspring with no apparent problems. Histological sections of heart, liver, skeletal muscle, and kidney from 3-month-old mice appear normal. The absence of H-FABP mRNA and protein in tissues of nullizygous mice was confirmed by Northern (Fig. 1C) and Western (Fig. 1D) To investigate LCFA utilization in vivo, the uptake of 125 I-BMIPP, a non-␤-oxidizable LCFA analog (22) , was determined for various organs. As shown in Fig.  2A , liver uptakes of 125 I-BMIPP are identical in normal and H-FABP null mice, whereas the normally high cardiac uptake is greatly reduced in the knockout mice. Similar results were obtained from skeletal muscles (M. soleus), although the control uptake into this tissue was relatively low as the mice did not exercise during labeling. This shows that at least in the heart, H-FABP has to be present to extract LCFA efficiently from the bloodstream. The effect on fatty acid uptake is specific, as the uptake of the glucose tracer analog 14 C-deoxyglucose is not reduced in knockout mice ( Fig. 2A) . Instead, there is a substantial increase of cardiac 14 C-deoxyglucose uptake in H-FABP-deficient mice, suggesting that glucose substitutes for LCFA as an energy substrate in this organ.
Additional evidence for a reduction in peripheral LCFA usage was sought by investigating plasma levels of key energy substrates under standard conditions (free access to mixed diet) and conditions favoring fatty acid oxidation (starvation, ketogenic diet) (Fig. 2B) . In H-FABP-deficient mice, free fatty acid plasma levels are increased compared with wild-type mice under all conditions, indicating a reduced utilization. Furthermore, the increase of ␤-hydroxybutyrate levels seen with a high-fat/carbohydrate-free diet is much more pronounced in the H-FABP nullizygous mice, consistent with the notion that part of the excess plasma LCFAs is converted to ketone bodies in the liver, where LCFA utilization is not reduced. Glucose levels of H-FABP-deficient mice showed a greater decrease on starvation or high-fat diet than wild-type controls, suggesting that carbohydrates are used more intensely in H-FABP-deficient mice. Lactate levels were slightly lower in the knockout mice but only significantly so in fasting mice. No differences were observed for triglyceride and cholesterol levels.
Pharmacological inhibition of mitochondrial (23) or cellular (24) fatty acid uptake, a fat-free diet (25) , as well as inborn diseases of fatty acid oxidation and transport (26 -28) have all been associated with cardiac hypertrophy. Therefore, we investigated whether H-FABP-deficient mice develop a similar abnormality. Figure 3A shows a 38fold (PϽ0.0005, nϭ6 per genotype) increase of ANP mRNA, a prototypical marker of cardiac hypertrophy (29) , in cardiac ventricles of 3-month-old H-FABP-deficient mice. By 10 -12 months of age, H-FABP-deficient, but not wild-type, hearts developed overt histological changes consistent with cardiac hypertrophy, which include a massive enlargement of myocyte nuclei (Fig. 3B ) and an increase of mean muscle fiber diameter (from 9.5 to 14.1 M; PϽ0.0005, nϭ3 per genotype) (Fig. 3C) . These changes are limited to the septum and near-luminal muscle layers (particularly of the left ventricle) of the heart chambers. Total heart weights and heart/body weight ratios of old nullizygous mice are increased moderately but significantly (PϽ0.05) by ϳ10%, as compared with controls, reflecting the localized character of the hypertrophy.
To test the limit of compensation, 24 nullizygous and 23 wild-type mice 3 months of age were subjected to an exercise regimen of repetitive swimming (30) . Six nullizygous mice (25%) and one wild-type animal (Ͻ5%) died during swimming (Fig. 4A) . Survivors were observed for signs of exhaustion. 'Exhaustion' was difficult to assess during swimming, but the phenomenon was easily assessed in the post-training period. Normal animals started grooming immediately after swimming; they moved around and their fur dried quickly. Exhausted animals did not move, their fur remained wet, and it took them up to 60 min to recover (Fig. 4B) . Fifteen nullizygous mice showed exhaustion once or repeatedly on 14 out of 30 training days, whereas only seven wild-type animals were exhausted on 3 days (Fig. 4A) . These results strongly suggest that H-FABP deficiency becomes deleterious under circumstances requiring heart and skeletal muscle work. Figure 4 suggests that decompensation (i.e., exercise intolerance) arises acutely, as there is no cumulative effect of training; correspondingly, light microscopy did not reveal differences between the hearts and skeletal muscles of trained nullizygous and wild-type mice.
DISCUSSION
It had not been clear previously whether FABP expression merely accompanies high cellular fluxes of LCFAs or is required for their intracellular utili- zation (4, 5) . The data in Fig. 2A show that H-FABP expression is indeed a prerequisite for a high flux of LCFAs in the heart and that there is no redundancy in that function. Cardiac levels of mRNAs encoding the sarcolemmal and outer mitochondrial membrane LCFA transporters, FAT and CPT1, as well as the mitochondrial ␤-oxidation enzyme, LCAD, are maintained. Given the previously published results (summarized in refs 4 and 5) that in the heart, H-FABP is mainly expressed in the soluble cytoplasm of cardiomyocytes (rather than endothelium or connective tissue), that it binds LCFAs, lacks enzymatic function, and its expression parallels LCFA oxidation, our results provide the main missing piece of evidence to conclude that H-FABP directly mediates LCFA transport in cardiomyocytes.
The dramatic metabolic shifts that accompany H-FABP deficiency (Fig. 2B) demonstrate that H-FABP expression is a major determinant of the pattern of fuel consumption in the body. These changes cannot be due to cardiac involvement alone but are likely to also involve other organs normally expressing H-FABP, notably skeletal muscles ( Fig.  2A) . Like the heart, skeletal muscles do not appear to express other FABPs as judged by Northern and Western blotting. LCFA transport deficiency in H-FABP nullizygous mice is clearly distinguished from all known cases of heritable CPTI defects, from systemic carnitine deficiency, and from pharmacological CPTI inhibition. Unlike these conditions, H-FABP deficiency does not impair hepatic ␤-oxidation but rather stimulates it, explaining why H-FABPdeficient mice tolerate starvation well and providing for the first time an animal model with which to study the role of peripheral LCFA oxidation. It is also different from those hereditary human CPTII defects that do not present with overt liver disease in that the latter are only partial and affect the enzyme throughout the body (see ref 31 for a review of the CPT system and its mutations). It will be interesting to see in more detail how in H-FABP-deficient mice, heart and skeletal muscle fibers cope with impaired LCFA metabolism and cooperate with the liver to overcome it. The mechanism of increased glucose uptake, the metabolic fate of the glucose, the energy status of H-FABP-deficient hearts and other peripheral organs (especially skeletal muscles) at rest and work, and the precise reason for exercise intolerance all deserve further investigation.
At old age, H-FABP-deficient mice develop a regional cardiac hypertrophy, which is restricted to the septum and ventricle muscle layers near the lumina of the heart chambers. This picture is reminiscent of the asymmetrical septal hypertrophy (ASH) occurring in humans deficient for CD36, a cardially expressed putative plasma membrane LCFA transporter (27) . H-FABP deficiency may therefore provide a model for some human cardiomyopathies thought to be caused by depressed myocardial LCFA utilization (26) and may be used to investigate the currently unknown mechanism linking altered fuel selection and cardiac hypertrophy. Furthermore, our finding raises the possibility that mutations in the H-FABP gene may be responsible for unexplained cases of hereditary ASH. The lack of redundancy for H-FABP function contrasts with observations on mice lacking the adipocyte FABP (aP2, or ALBP), which suggests a pathophysiological role for ALBP. ALBP-deficient mice activate the E-FABP gene in their adipocytes and on a normal diet do not exhibit a metabolic defect. However, on a high fat diet, they fail to develop insulin resistance (9), possibly because E-FABP expression copes only with basal but not increased needs for LCFA transport. Increased LCFA transport may be a prerequisite for insulin resistance. Thus, although ALBP-deficient mice do not prove a role of ALBP or E-FABP in LCFA transport, their phenotype is consistent with this role. In contrast, H-FABP-deficient mice directly prove the importance of FABP for LCFA transport. They should be suitable models with which to examine the relationship between cellular LCFA fluxes and muscle insulin sensitivity under both normal and high-fat dietary intake. Such experiments will require that the H-FABP gene deletion be back-crossed onto a C57/Bl6 inbred background.
In conclusion, H-FABP-deficient mice establish a major role of H-FABP in cellular lipid transport. They provide the first demonstration of a physiological role for a member of the large and widely expressed FABP gene family and suggest that other FABPs may also be suitable targets to manipulate LCFA metabolism. H-FABP-deficient mice may be useful when investigating some clinically relevant effects of reduced LCFA utilization, such as cardiac hypertrophy (see above), improved ischemic heart function (32), reduced high blood pressure (33) , or increased insulin sensitivity (33; foregoing discussion), and to assess the contribution of peripheral tissues vs. liver/white fat in these phenomena. Other hypothesized functions of H-FABP, such as the protection of reperfused myocardium (5) or of arterial walls (34) from the toxic effects of fatty acids or modulation of proliferation and differentiation (35) may now also be verified using this model. 
